BridgeMD
New treatment option for Post-Stroke Cognitive Impairment (PSCI)
Official title High-Frequency Repetitive Transcranial Magnetic Stimulation for Cognitive Improvement in Patients With Post-Stroke Cognitive Impairment
ClinicalTrials.gov ID: NCT07546877
What this study is testing
- What it's testing
- To clarify the clinical efficacy of high-frequency rTMS on patients with post-stroke cognitive impairment, fNIRS and EEG techniques were used to observe the changes in brain functional activities of patients with post-stroke cognitive impairment after rTMS treatment, and to clarify the neuroregulatory effect of rTMS on patients with post-stroke cognitive impairment.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 35 to 75
You may be able to join if
- Meets the diagnostic criteria for stroke as stipulated in the "Guidelines for the Prevention and Treatment of Stroke in China (2021 Edition)", and...
- The disease course is 1-12 months;
- Has cognitive impairment (MoCA \< 26 points, education years ≤ 12 years, add 1 point to the score result);
- Age 35-75 years old, gender not limited;
- Stable vital signs, no progressive neurological symptoms;
You likely can't join if
- Has a history of brain tumors, brain trauma, epilepsy or mental disorders;
- Had cognitive impairment before the stroke;
- Underwent craniotomy or had a skull defect;
- Had implanted metal or electronic devices (such as cardiac pacemakers, cochlear implants, deep brain stimulators, aneurysm clips, internal fixation...
- Has other serious diseases that may affect the study;
- Pregnant women
See the full eligibility criteria
- Meets the diagnostic criteria for stroke as stipulated in the "Guidelines for the Prevention and Treatment of Stroke in China (2021 Edition)", and the initial stroke diagnosis is confirmed by cranial CT or MRI...
- The disease course is 1-12 months;
- Has cognitive impairment (MoCA \< 26 points, education years ≤ 12 years, add 1 point to the score result);
- Age 35-75 years old, gender not limited;
- Stable vital signs, no progressive neurological symptoms;
- No severe aphasia, visual or auditory impairment, and able to complete the research protocol;
- Not using antidepressant drugs simultaneously;
- If using cognitive-improving drugs (such as donepezil, memantine), it should last for at least 3 weeks or more, and no dose adjustment will be made during the enrollment period;
- Voluntarily participate and sign the informed consent form.
- Has a history of brain tumors, brain trauma, epilepsy or mental disorders;
- Had cognitive impairment before the stroke;
- Underwent craniotomy or had a skull defect;
- Had implanted metal or electronic devices (such as cardiac pacemakers, cochlear implants, deep brain stimulators, aneurysm clips, internal fixation devices after ventriculoperitoneal shunt surgery, etc.);
- Has other serious diseases that may affect the study;
- Pregnant women
The study team makes the final eligibility decision.
Where it's taking place
- Jinan, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 35 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Jinan, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.